Luc Gagnon, IQVIA Laboratories’ global head of vaccine sciences, appointed to CEPI’s Global Central Laboratory Network Advisory Council

RESEARCH TRIANGLE PARK, N.C. – IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, is proud to announce that Luc Gagnon, global head of vaccine sciences, has been appointed to the newly formed Global Central Laboratory Network Advisory Council (GCAC) by the Coalition for Epidemic Preparedness Innovations (CEPI).

The GCAC was established to strengthen the role of CEPI’s Centralized Laboratory Network (CLN) by ensuring that its 18 global laboratories are more actively engaged in critical decision-making processes. IQVIA Laboratories is one of the 18 labs in that network. Gagnon, along with the other council members, will work with all 18 of the global laboratories to ensure each lab is actively engaged in critical decision-making processes. This initiative marks a significant step forward in addressing both current and future challenges in epidemic preparedness and response.

Gagnon has been global head of vaccine sciences for IQVIA Laboratories since January 2022. He previously served as vice president of vaccine services at Nexelis, and prior to that worked at GlaxoSmithKline and other life sciences companies. He holds Ph.D., Master’s and Bachelor’s degrees in Biochemistry/Microbiology and Immunology from Université Laval in Quebec and was a post-doctoral fellow in Microbiology/Molecular Biology at Université du Québec à Trois-Rivières.

Gagnon’s appointment to the GCAC follows a competitive selection process in which six distinguished individuals were chosen to represent the diverse expertise across the CLN. As a GCAC member, he will contribute to:

• Supporting the CLN in responding to urgent matters regarding global epidemics and public health concerns.
• Facilitating assay development, validation and transfer while streamlining processes to meet quality and regulatory standards.
• Collaborating with other facilities to overcome scientific and logistical challenges.
• Providing strategic guidance and feedback to CEPI leadership on key initiatives.

The GCAC will convene bi-monthly with an extended team that includes representatives from each facility to foster broader engagement and support across the network. While the GCAC will play a pivotal advisory role, technical and logistical communications regarding assay development will continue to be managed directly by the CEPI-CLN team.

“Luc’s expertise has played a pivotal role in driving innovative solutions and ensuring that our laboratory insights contribute meaningfully to the global fight against infectious diseases,” said Tony Brown, VP & GM of Specialty Labs. “His appointment to the GCAC reflects both his personal dedication and IQVIA Laboratories’ ongoing commitment to advancing global health through scientific excellence and collaboration.”

About IQVIA Laboratories
IQVIA Laboratories is a leading global drug discovery and development laboratory services organization offering a comprehensive suite of central laboratory and specialty biomarker services. Our expertise spans central laboratory, genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine, vaccine, ADME, and bioanalytical services. IQVIA Laboratories also brings extensive expertise in antibody drug discovery, biomarker discovery, and decentralized clinical trial laboratory solutions.

With a commitment to scientific excellence and operational efficiency, IQVIA Laboratories supports the entire drug development life cycle across diverse regions and regulatory landscapes, ensuring data integrity and optimizing research to bring life-changing therapies to patients faster. To learn more visit www.labs.iqvia.com.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

About CEPI
The Coalition for Epidemic Preparedness Innovations (CEPI) is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI leverages its unique position within the global health and R&D ecosystems to address market failures, building on its track record of bringing together public-sector, private-sector, and academic partners to accelerate the development of vaccines against emerging viral threats.